• PSN12 NAIL PSORIASIS- ELABORATION OF A SCALE FOR FUNCTIONAL DISCOMFORT

    Nov 1, 2005, 00:00

  • IN3 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS LIPOSOMALAMPHOTERICIN B FOR INVASIVE ASPERGILLOSIS INFECTION IN THE UK

    Nov 1, 2005, 00:00

  • PHP8 RESOURCE CONSUMPTION IN PLATELET PRODUCTION FROM THE PERSPECTIVE OF A TRANSFUSION MEDICINE DEPARTMENT IN GERMANY

    Nov 1, 2005, 00:00

  • DN2 COST-UTILITY ANALYSIS IN A UK SETTING OF SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PPN5 A MODEL-BASED COST-UTILITY ANALYSIS OF LYRICA™(PREGABALIN) VERSUS CURRENT PHARMACEUTICAL MANAGEMENT OF PERIPHERAL NEUROPATHIC PAIN

    Nov 1, 2005, 00:00

  • PCV12 MANAGEMENT PATTERNS AND COSTS OF ATRIAL FIBRILLATION IN A LARGE COMMERCIALLY INSURED U.S. POPULATION

    Nov 1, 2005, 00:00

  • PDB62 TREATMENT SATISFACTION IN SUBJECTS WITH TYPE-2 DIABETES RECEIVING INSULIN GLARGINE

    Nov 1, 2005, 00:00

  • PMH17 HEALTH RELATED QUALITY OF LIFE (HRQOL) AND BURDEN OF FAMILY CAREGIVERS OF DIALYSIS PATIENTS

    Nov 1, 2005, 00:00

  • QL7 IMPACT OF LUTS ON QUALITY OF LIFE IN ITALIAN WOMEN

    Nov 1, 2005, 00:00

  • PUK19 EXPLORING NEUROGENIC DETRUSOR OVERACTIVITY WITHIN AN OVERACTIVE BLADDER POPULATION

    Nov 1, 2005, 00:00

  • PGI23 ESOMEPRAZOLE TREATMENT IN PATIENTS WITH UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO SIGNIFICANT IMPROVEMENTS IN PRODUCTIVITYWHILE ATWORKAND IN DAILY ACTIVITIES—RESULTS FROMA RANDOMISED, PLACEBO-CONTROLLED CLINICAL STUDY

    Nov 1, 2005, 00:00

  • PUK34 EVALUATION OF TWO TENSION FREE VAGINAL TAPES WITH URODYNAMICS AND ICIQ-UI SF QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • IN4 LOWERING THE AGE THRESHOLD FOR ROUTINE INFLUENZA VACCINATION- AN ECONOMIC EVALUATION FOR FOUR EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PSU3 THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING COLORECTAL SURGERY

    Nov 1, 2005, 00:00

  • PDB36 COST OF TYPE-2 DIABETES MELLITUS IN HONG KONG CHINESE

    Nov 1, 2005, 00:00

  • PRS20 PATIENT REPORTED IMPACT OF COUGH AND SPUTUM IN CHRONIC (OBSTRUCTIVE) BRONCHITIS—SIMULTANEOUS DEVELOPMENT OF THE SELF-ADMINISTERED CASA-Q

    Nov 1, 2005, 00:00

  • PRS11 MANAGEMENT OF COPD IN BELGIUM- A REAL LIFE COST OF ILLNESS STUDY

    Nov 1, 2005, 00:00

  • PCV73 USE OF PROPENSITY SCORE METHODOLOGY IN CARDIOVASCULAR DEVICE TRIALS- U.S. FOOD AND DRUG ADMINISTRATION PERSPECTIVES

    Nov 1, 2005, 00:00

  • PCN40 DEVELOPMENT OF AN ALGORITHM FOR THE IDENTIFICATION AND CLASSIFICATION OF COLORECTAL CANCER (CRC) PATIENTS ACCORDING TO FIRST-LINE CHEMOTHERAPY +/− BEVACIZUMAB, AND INITIATION OF SECOND-LINE THERAPY USING ADMINISTRATIVE CLAIMS RECORDS

    Nov 1, 2005, 00:00

  • PHP43 IMPACT OF PHARMACEUTICAL POLICIES ON PROMOTIONAL TARGETED DRUGS

    Nov 1, 2005, 00:00

  • PEY1 ANXIETY AND DEPRESSION IN WET AGE-RELATED MACULAR DEGENERATION (ARMD)

    Nov 1, 2005, 00:00

  • PMD3 A COST EFFECTIVENESS MODEL FOR THE EVALUATION OF TOTAL HIP ARTHROPLASTY (THA) AND TOTAL KNEE ARTHROPLASTY (TKA) IN SWEDEN

    Nov 1, 2005, 00:00

  • PCV45 THE ECONOMIC ASSESSMENT OF SWITCHING TO DUAL INHIBITION CHOLESTEROL LOWERING THEARPY IN FINLAND

    Nov 1, 2005, 00:00

  • PMH4 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS- MENTAL HEALTH AND PHYSICAL CO-MORBIDITY IN NORDBADEN/GERMANY

    Nov 1, 2005, 00:00

  • PHP30 PRESCRIBING PATTERNS AND ASSOCIATED COSTS OF PSYCHOTROPIC DRUGS IN A MAJOR HEALTH CARE SYSTEM IN SAUDI ARABIA

    Nov 1, 2005, 00:00

  • PMC18 PSYCHOMETRIC PROPERTIES OF A TOUCH SCREEN COMPUTER-BASED VERSION OF THE SF-36

    Nov 1, 2005, 00:00

  • QL3 “FAMIDIAL STUDY”- ANALYSIS OF THE DIFFERENCES BETWEEN DIALYSIS PATIENTS AND THEIR CAREGIVERS (FAMILY CARERS, NURSES AND DOCTORS) ON DIALYSIS PATIENTS' HRQOL, AND OF THE FAMILY CARERS' HRQOL AND BURDEN

    Nov 1, 2005, 00:00

  • PMC11 DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A U.S. MEDICAID POPULATION

    Nov 1, 2005, 00:00

  • PMC17 RASCH ANALYSIS OF THE FATIGUE IMPACT SCALE

    Nov 1, 2005, 00:00

  • PUK28 LONG-TERM DARIFENACIN TREATMENT FOR OVERACTIVE BLADDER- QUALITY OF LIFE OUTCOMES FROM A 2-YEAR, OPEN-LABEL EXTENSION STUDY

    Nov 1, 2005, 00:00

  • PCN9 COST COMPARISON ANALYSIS OF INTRAVENOUS VERSUS COMBINED INTRAVENOUS-ORAL CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2005, 00:00

  • PDB29 HEALTH ECONOMIC EVALUATION OF INSULIN GLARGINE FOR THE TREATMENT OF TYPE-1 AND TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PNL3 RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE

    Nov 1, 2005, 00:00

  • PCN15 PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER

    Nov 1, 2005, 00:00

  • PGI8 ECONOMIC EVALUATION OF ADACOLUMN® APHERESIS FOR THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE (CD)/ULCERATIVE COLITIS (UC)

    Nov 1, 2005, 00:00

  • PAS7 THE HUMAN IMPACT OF SEVERE PERSISTENT ALLERGIC ASTHMA- RESULTS FROM A MULTINATIONAL STUDY

    Nov 1, 2005, 00:00

  • QL8 QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS- THE COCHE STUDY

    Nov 1, 2005, 00:00

  • PCV63 CARDIOVASCULAR DRUG USE IN NIS REGION

    Nov 1, 2005, 00:00

  • PAS8 ASTHMA RELATED QUALITY OF LIFE IS CORRELATED WITH ASTHMA CONTROL AMONG RESPIRE STUDY PARTICIPANTS

    Nov 1, 2005, 00:00

  • PDB43 SHOULD WE LOOK FOR A NEWAPPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?

    Nov 1, 2005, 00:00

  • PST9 MANDARIN VERSION OF STROKE IMPACT SCALE- ADAPTATION AND VALIDATION

    Nov 1, 2005, 00:00

  • PHP48 A SURVEY OF PATIENT REPORTED OUTCOME (PRO) CLAIMS IN PHARMACEUTICAL ADVERTISING

    Nov 1, 2005, 00:00

  • PHP27 PREDICTIVE VALUE OF PHARMACEUTICAL TREATMENT (PT) COST AND LENGTH OF STAY (LOS) ON TOTAL HOSPITAL (TH) COST USING THE MINIMUM BASIC DATA SET (MBDS)

    Nov 1, 2005, 00:00

  • CV3 A COST-EFFECTIVENESS ANALYSIS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE

    Nov 1, 2005, 00:00

  • PUK14 COST OF ILLNESS OF FEMALE LOWER URINARYTRACT SYMPTOMS (LUTS)

    Nov 1, 2005, 00:00

  • PFM1 FIBROMYALGIA SYNDROME- A PORTUGUESE EPIDEMIOLOGICAL SURVEY

    Nov 1, 2005, 00:00

  • PGI17 ARTIFICIAL LIVER SUPPORT SYSTEMS—A MEDICAL AND HEALTH ECONOMIC HTA-REPORT

    Nov 1, 2005, 00:00

  • PIN26 COST-EFFECTIVENESS OF PREVENTING OF RECURRENT UPPER RESPIRATORYTRACT INFECTIONS WITH NONSPECIFIC IMMUNOSTIMULATING BACTERIAL EXTRACT

    Nov 1, 2005, 00:00

  • PSN9 PATTERNS OF TOPICAL ACNE PRESCRIPTION MEDICATION USE- ANALYSIS OF A LARGE-SCALE RETROSPECTIVE CLAIMS DATABASE

    Nov 1, 2005, 00:00

  • PHP31 CHARGES FOR HOSPITAL ADMISSIONS ATTRIBUTABLE TO HEALTH DISPARITIES FOR AFRICAN AMERICAN PATIENTS IN SOUTH CAROLINA DURING 1998-2002

    Nov 1, 2005, 00:00

  • PMC9 THE OPTIMAL COST-EFFECTIVENESS RATIO THRESHOLD IN CASE OF CO-MORBIDITIES

    Nov 1, 2005, 00:00

  • PMH38 A DISCRETE EVENT SIMULATION (DES) MODEL TO DESCRIBE SCHIZOPHRENIA

    Nov 1, 2005, 00:00

  • PHP39 PUBLIC FUNDING OF DRUGS FOR ORPHAN DISEASES

    Nov 1, 2005, 00:00

  • PSN17 VALIDATION OF THE ITALIAN VERSION OF THE INFANTS' DERMATITIS QUALITY OF LIFE FAMILY DERMATITIS INDEXES

    Nov 1, 2005, 00:00

  • PMH44 DULOXETINE AND VENLAFAXINE-XR IN THE TREATMENT OF MDD- A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

    Nov 1, 2005, 00:00

  • PED2 LONG-TERM QUALITY OF LIFE (QOL) OUTCOMES IN THE TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY (GHD)—A 5 YEAR STUDY

    Nov 1, 2005, 00:00

  • PCV84 SURGICAL TREATMENT OF ABDOMINAL AORTIC ANEURISM- ANALYSIS OF OPERATING COSTS. ENDOVASCULAR TREATMENT VERSUS TRADITIONAL SURGERY

    Nov 1, 2005, 00:00

  • PNL7 IS THE TREATMENT OF ACUTE MIGRAINE WITH TRIPTANS EFFICIENT FROM A SOCIETAL PERSPECTIVE?

    Nov 1, 2005, 00:00

  • POS2 CLINICAL EFFICACY AND SAFETY OF BALLOON KYPHOPLASTY FOR THE TREATMENT OF VERTEBRAL COMPRESSION FRACTURES- A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2005, 00:00

  • PUK9 COST-EFFECTIVENESS OF PARICALCITOL IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM- THE EXPERIENCE IN ITALY

    Nov 1, 2005, 00:00

  • PDB18 COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA- A UK PERSPECTIVE

    Nov 1, 2005, 00:00

  • PEY15 COST OF ENDOPHTHALMITIS- A NATIONWIDE APPROACH

    Nov 1, 2005, 00:00

  • Assessing Patient Satisfaction- Concepts, Applications, and Measurement

    Nov 1, 2005, 00:00

  • PMC10 A METHODOLOGICAL APPROACH TO ASSESS COST DATA IN THE CONTEXT OF A DECISION ANALYTIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF THE METABOLIC SYNDROME

    Nov 1, 2005, 00:00

  • CN4 COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER

    Nov 1, 2005, 00:00

  • PGI11 IBD- INDIRECT COSTS OF ILLNESS AND QUALITY OF LIFE IN GERMANY

    Nov 1, 2005, 00:00

  • PCV44 COST-EFFECTIVENESS OF ROSUVASTATIN IN THE PREVENTION OF ISCHEMIC HEART DISEASE IN PORTUGAL

    Nov 1, 2005, 00:00

  • PIH7 QUALITY OF LIFE OF ITALIAN GENERAL POPULATION AGED 40 TO 79 YEARS OLD

    Nov 1, 2005, 00:00

  • POB2 PREVALENCE TRENDS IN OVERWEIGHT AND OBESITY AND WEIGHT CONTROL PRACTICES AMONG ADULTS IN THE US

    Nov 1, 2005, 00:00

  • PUK31 DEVELOPMENT AND PILOT TESTING OF A NEW SCALE SPECIFICALLY MEASURING THE IMPACT OF STRESS URINARY INCONTINENCE (SUI) ON COMMON PHYSICAL ACTIVITIES OF DAILY LIFE

    Nov 1, 2005, 00:00

  • PIN14 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION- ESTIMATES FROM INFECTED AMERICANS

    Nov 1, 2005, 00:00

  • PGI19 GASTROESOPHAGEAL REFLUX DISEASE (GERD) COST OF CARE- ROLE OF NAÏVE AND RELAPSED SYMPTOMS IN GENERAL PRACTICE

    Nov 1, 2005, 00:00

  • PCN50 A PILOT STUDY ASSESSING THE QUALITY OF LIFE IMPACT OF ADVERSE EVENTS EXPERIENCED BY ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • POB9 EVALUATION OF THE ASSOCIATION BETWEEN BODY MASS INDEX, WAIST CIRCUMFERENCE AND HEALTH-RELATED UTILITY (EQ5D)

    Nov 1, 2005, 00:00

  • PMD2 COST-EFFECTIVENESS ANALYSIS OF ACLASTA IN PAGET'S DISEASE OF BONE IN BELGIUM

    Nov 1, 2005, 00:00

  • PIN21 SELF ASSESSED HEALTH-RELATED QUALITY OF LIFE AMONG HIV PATIENT IN UK

    Nov 1, 2005, 00:00

  • PGI18 META-ANALYSIS OF MULTIPLE TREATMENT COMPARISONS REPORTED AT MULTIPLE FOLLOW-UP TIMES

    Nov 1, 2005, 00:00

  • PGI2 COST EFFECTIVENESS AND BUDGET IMPACT OF LAMIVUDINE ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS TYPE B PATIENTS IN TAIWAN

    Nov 1, 2005, 00:00

  • PMH48 QUALITY OF LIFE IN MAJOR DEPRESSION- RESULTS OF THE MC3 TRIAL

    Nov 1, 2005, 00:00

  • PEY2 USE OF NEURAL NETWORKS TO PREDICT NIGHT INTRA-OCULAR PRESSURE (IOP) PEAK CONTROL BY PROSTAGLANDIN ANALOGUES

    Nov 1, 2005, 00:00

  • QL4 VARIABILITY IN QOL QUESTIONNAIRES AND THE HANDLING OF MISSING DATA IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • PHP2 IMPLEMENTATION OF AN EVIDENCE BASED GUIDELINE FOR CLINICAL NUTRITION IN A 500 BED HOSPITAL IN NORTHERN GERMANY- INFLUENCE ON DIRECT COST FOR CLINICAL NUTRITION

    Nov 1, 2005, 00:00

  • PCN17 THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN FORTHE TREATMENT OF PATIENTS WITH EGFR-EXPRESSING METASTATIC COLORECTAL CANCER AFTER FAILURE OF IRINOTECAN-INCLUDING CYTOTOXIC THERAPY IN SCOTLAND

    Nov 1, 2005, 00:00

  • PPN10 PSYCHOMETRIC PROPERTIES OF THE MOS-SLEEP SCALE IN NEUROPATHIC PAIN (NEP) SYNDROMES

    Nov 1, 2005, 00:00

  • PHP34 EFFECTS OF MEDICAL SAVINGS ACCOUNTS ON HEALTH CARE UTILIZATION AND HEALTH EXPENDITURE- EVIDENCE FROM CHINA

    Nov 1, 2005, 00:00

  • PUK1 THE TIMELY CONSTRUCTION OF AN ARTERIOVENOUS FISTULAE- A KEY FACTOR IN REDUCING MORBIDITY AND MORTALITY AND IMPROVING ECONOMIC EFFECTIVENESS

    Nov 1, 2005, 00:00

  • PMH20 RELATION BETWEEN SYMPTOMS IN SCHIZOPHRENIA AND RISK OF HARM TO SELF AND OTHERS

    Nov 1, 2005, 00:00

  • PMC16 THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM (NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH REGISTRY

    Nov 1, 2005, 00:00

  • PUK11 COST ANALYSIS OF RENAL REPLACEMENT THERAPIES IN LATVIA

    Nov 1, 2005, 00:00

  • PSN13 REFINEMENT AND REDUCTION OF THE IMPACT OF PSORIASIS QUESTIONNAIRE- CLASSICAL TEST THEORY VS RASCH ANALYSIS

    Nov 1, 2005, 00:00

  • PED4 SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PMH12 THE NORDBADEN PROJECT FOR HEALTH CARE UTILIZATION RESEARCH IN GERMANY

    Nov 1, 2005, 00:00

  • PNL8 COST-EFFECTIVENESS OF BETAHISTINE VS CINNARIZINE FOR VERTIGO

    Nov 1, 2005, 00:00

  • POS9 EXTENDING THE BURDEN OF DISEASE PROTOCOL- DERIVING DISABILITY WEIGHTS FOR RISK FACTOR DISEASES—THE CASE FOR OSTEOPOROSIS

    Nov 1, 2005, 00:00

  • PHP5 COST OF SEVERE BLUNT TRAUMA IN THE UK

    Nov 1, 2005, 00:00

  • Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective

    Nov 1, 2005, 00:00

  • PCV28 IMPACT OF MODIFIED SYSTEM OF OBJECTIFIED JUDGMENT ANALYSIS (SOJA) METHODOLOGY ON PRESCRIBING COSTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIS)

    Nov 1, 2005, 00:00

  • PAR17 BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY

    Nov 1, 2005, 00:00

  • PDB22 ASSESSING THE EFFICIENCY OF USING CONTINUOUS SUBCUTANEOUS INSULIN-INFUSION (CSII) VERSUS MULTIPLE DAILY INJECTIONS (MDI) IN SPANISH DIABETES MELLITUSTYPE-I (DM I) PATIENTS. COST—EFFECTIVENESS ANALYSIS

    Nov 1, 2005, 00:00

  • PNL9 COST-EFFECTIVENESS OF ALTERNATIVE POLIO IMMUNIZATION POLICIES IN SOUTH AFRICA

    Nov 1, 2005, 00:00

  • PCV86 THE ECONOMIC BURDEN OF EXPERIENCING MAJOR COMPLICATIONS DURING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2005, 00:00

  • PEY14 IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY

    Nov 1, 2005, 00:00

  • PHM5 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA WITH THE NEWLY DEVELOPED HAEMOPHILIA-SPECIFIC INSTRUMENT HAEM-A-QOL

    Nov 1, 2005, 00:00

  • MC1 USE OF A MODIFIED RECURSIVE PARTITIONING AND AMALGAMATION (RECPAM)TECHNIQUE IN OUTCOMES RESEARCH

    Nov 1, 2005, 00:00

  • PIH10 COST-EFFECTIVENESS STUDY OF ASSISTED REPRODUCTIVE TECHNIQUES IN SPAIN

    Nov 1, 2005, 00:00

  • PUK10 COST-EFFECTIVENESS OF MIMPARAAMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL

    Nov 1, 2005, 00:00

  • PDB6 REDUCTION IN DIABETES DRUGS USE AND DRUG COSTS IN OBESE PEOPLE TREATED WITH ORLISTAT

    Nov 1, 2005, 00:00

  • Hierarchical Construct Validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among Outpatient Pharmacy Consumers

    Nov 1, 2005, 00:00

  • PSN10 THE RISE OF THE GENERIC DRUG MARKET- IMPLICATIONS FOR THE TREATMENT OF SKIN DISEASES

    Nov 1, 2005, 00:00

  • PCN16 ADDING RITUXIMABTO STANDARD CHEMOTHERAPY APPEARS DOMINANT VS. CHEMOTHERAPY ALONE IN ADVANCED STAGE NHL—INTERIM RESULTS FROM A RANDOMIZED CLINICAL TRIAL (RCT)

    Nov 1, 2005, 00:00

  • PCV8 COST OF HOSPITALIZATION FOR PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN POLAND

    Nov 1, 2005, 00:00

  • MC5 ON EVALUATING COST ASSOCIATED WITH EVENT-CENSORED DATA APPLICATION TO ALL-CAUSE GRAFT FAILURE FOLLOWING KIDNEYTRANSPLANTATION

    Nov 1, 2005, 00:00

  • PCV30 CLOPIDOGREL LOADING DOSE AND CARDIOVASCULAR OUTCOMES IN ACUTE CORONARY SYNDROME PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2005, 00:00

  • PST6 FACTORS RELATED TO LONGER HOSPITAL STAY AFTER FIRST-EVER ISCHEMIC STROKE

    Nov 1, 2005, 00:00

  • PIN9 A COST UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A (40 KD) VERSUS PEGINTERFERON ALFA-2B (I2KD) FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN THE UK

    Nov 1, 2005, 00:00

  • PHP25 USING AN ITALIAN POPULATION DATABASE TO PROFILE PREVALENCE AND COSTS OF CHRONIC CONDITIONS

    Nov 1, 2005, 00:00

  • PRS12 THE BURDEN OF LUNG DISEASE (BOLD) ECONOMIC MODEL

    Nov 1, 2005, 00:00

  • PIH4 WHAT METHODS OF ASSESSMENT AND MANAGEMENT OF ELDERLY PEOPLE ARE COST EFFECTIVE

    Nov 1, 2005, 00:00

  • POS10 PERSISTENCE OF DRUG TREATMENT WITH ALENDRONATE AND RISEDRONATE IN PRIMARY CARE PATIENTS

    Nov 1, 2005, 00:00

  • PDB38 ANALYSIS OF THE COST OF DIABETES TREATMENT IN BULGARIA

    Nov 1, 2005, 00:00

  • PCV48 ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN) IN SPAIN

    Nov 1, 2005, 00:00

  • The Validation of Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue—The BSW

    Nov 1, 2005, 00:00

  • PHP41 EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE REIMBURSEMENT AGENCIES IN SWEDEN AND FINLAND—A CROSS COUNTRY COMPARISON

    Nov 1, 2005, 00:00

  • PHP26 ADHERENCE INDEX OF PERFORMANCE—A NEW METHOD AND TOOL FOR ONGOING EVALUATION OF MEDICATION ADHERENCE IMPROVEMENT INITIATIVES

    Nov 1, 2005, 00:00

  • PAR18 PATIENT COMPLIANCE IN THE TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGIC DMARDS AND PREDICTING FACTORS- A LITERATURE REVIEW

    Nov 1, 2005, 00:00

  • PIN27 COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND LIPOSOMALAMPHOTERICIN B FOR THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS IN SPAIN

    Nov 1, 2005, 00:00

  • PCV23 ECONOMIC EVALUATION OFVALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE IN THE HUNGARIAN HEALTH CARE SETTING

    Nov 1, 2005, 00:00

  • PNL15 PREFERENCE FOR RECONSTRUCTIVE INTERVENTIONS OF THE UPPER EXTREMITIES IN TETRAPLEGIA- THE IMPACT OF TREATMENT CHARACTERISTICS

    Nov 1, 2005, 00:00

  • PDB14 COST OF DIABETES MELLITUS TYPE-2 AND SELF MEASUREMENT OF BLOOD GLUCOSE IN GERMANY- A HEALTH INSURANCE PERSPECTIVE

    Nov 1, 2005, 00:00

  • PCN35 A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)

    Nov 1, 2005, 00:00

  • PDB19 ECONOMIC EVALUATION OF SWITCHING TYPE-1 DIABETES PATIENTS FROM LONG-ACTING INSULIN GLARGINE INA BASAL/BOLUS REGIMEN TO LONG-ACTING INSULIN DETEMIR IN AN AUSTRIAN SETTING

    Nov 1, 2005, 00:00

  • CO3 META-REGRESSION ASSESSMENT OF ATOMOXETINE EFFICACY USING RANDOMIZED CONTROLLED ADHD TRIALS

    Nov 1, 2005, 00:00

  • PCN28 DOCUMENTATION OF PHARMACY COST IN THE PREPARATION OF CHEMOTHERAPY INFUSIONS IN ACADEMIC AND COMMUNITY-BASED ONCOLOGY PRACTICES

    Nov 1, 2005, 00:00

  • PPN8 THE MOS-SHORT-FORM-12 (SF-12) AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN NEUROPATHIC PAIN (NEP) PATIENTS- RELIABILITY, CONCURRENT AND DISCRIMINANT VALIDITY

    Nov 1, 2005, 00:00

  • PAR11 VALIDITY STUDIES AND SATISFACTION THRESHOLD OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)

    Nov 1, 2005, 00:00

  • PCN1 ECONOMIC IMPACT OF ADOPTING PEMETREXED PLUS CISPLATIN FOR MALIGNANT PLEURAL MESOTHELIOMA INTO SCOTTISH CLINICAL PRACTICE

    Nov 1, 2005, 00:00

  • PDB56 AN ASSESSMENT OF THE LONG-TERM OUTCOME FOR LIRAGLUTIDE+METFORMIN VERSUS METFORMIN AND VERSUS METFORMIN+GLIMEPIRIDE INTYPE-2 PATIENTS WITH INADE-QUATE GLYCAEMIC CONTROL

    Nov 1, 2005, 00:00

  • PHP20 GENERIC DRUG PRICES REMAIN HIGHER IN CANADA THAN IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PRS1 CLINICAL AND TREATMENT FACTORS INFLUENCING THE OUTCOME OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS- LESSONS FOR FURTHER CLINICAL AND OUTCOMES RESEARCH

    Nov 1, 2005, 00:00

  • PUK17 BENIGN PROSTATIC HYPERPLASIA- CROSS EVALUATION OF THE GP-PATIENT IPSS

    Nov 1, 2005, 00:00

  • PHP9 PHARMACEUTICAL CARE IN GREECE- A CITIZEN SATISFACTION SURVEY

    Nov 1, 2005, 00:00

  • PUK7 DELIVERING TREATMENT EFFECTIVENESS- COSTS AND PERSISTENCE OF TOLTERODINE IN THE MANAGEMENT OF OAB IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PCV29 USE OF CONTRAST ECHOCARDIOGRAPHY- A REVIEW OF CLINICAL DATA USING A SYSTEMATIC APPROACH

    Nov 1, 2005, 00:00

  • PCN34 COST-EFFECTIVENESS OF ANASTROZOLE OVERTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE- THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL

    Nov 1, 2005, 00:00

  • PED3 A PROSPECTIVE REAL-LIFE STUDY OF QUALITY OF LIFE IN PATIENTS WITH ACROMEGALY

    Nov 1, 2005, 00:00

  • PCN26 CUTANEOUS CANCER TREATMENT AND COSTS IN GERMANY

    Nov 1, 2005, 00:00

  • PDB45 PREDICTORS OF DIABETES MEDICATION UTILIZATION AND HEALTH CARE COSTS IN U.S. PATIENTS WITH TYPE-2 DIABETES- RESULTS FROM A NATIONAL SURVEY STUDY

    Nov 1, 2005, 00:00

  • PCV53 PATIENT PROFILE AND STATINS EFFECTIVENESS IN USUAL CARE

    Nov 1, 2005, 00:00

  • PMC20 INDIRECT COMPARISON (OR COMMON-COMPARATOR) METHODS FOR META-ANALYSIS OF SUMMARY DATA

    Nov 1, 2005, 00:00

  • PCV78 THE DIRECT COSTS OF SELECTED CARDIOVASCULAR DISEASES IN AUSTRIA

    Nov 1, 2005, 00:00

  • PMH41 REMISSION CRITERIA FOR DEPRESSION WHEN USING SHORT VERSIONS OF THE HAMILTON DEPRESSION RATING SCALE (HDRS)

    Nov 1, 2005, 00:00

  • PHP19 PRESCRIPTION DRUGS AND ANNUAL BENEFIT CAPS—DO PATIENTS ANTICIPATE EXCEEDING THE CAP?

    Nov 1, 2005, 00:00

  • PCN24 ESTIMATING THE COST OF INFORMAL CAREGIVING IN LUNG CANCER PATIENTS.THE HABIT STUDY

    Nov 1, 2005, 00:00

  • PDB52 TYPE-2 DIABETES MODELS THAT DO NOT ACCOUNT FOR MICROVASCULAR DISEASE SCREENING RATESAND IMPORTANT CONCOMITANT MEDICATION USE MAY LEAD TO SUBSTANTIAL MISREPRESENTATION OF THE COST-EFFECTIVENESS OF NEW MEDICATIONS

    Nov 1, 2005, 00:00

  • PIN17 COST-EFFECTIVENESS ANALYSIS OF ENFUVIRTIDE ADDED TO AN OPTIMISED THERAPYVS. AN OPTIMISED THERAPY ALONE IN PATIENTS WITH H.I.V/AIDS

    Nov 1, 2005, 00:00

  • PCV6 IMPACT OF STATIN THERAPY INTENSITY ON ALL-CAUSE MORTALITY FOLLOWING CARDIOVASCULAR HOSPITALIZATION IN A MANAGED CARE POPULATION

    Nov 1, 2005, 00:00

  • PHP21 PHARMACEUTICAL POLICY IN GREECE- RECENT DEVELOPMENTS AND THE ROLE OF PHARMACOECONOMICS

    Nov 1, 2005, 00:00

  • PCN18 LETROZOLE (FEMARA) IS A COST-EFFECTIVE TREATMENT IN THE EXTENDED ADJUVANT SETTING IN WOMEN WITH EARLY BREAST CANCER- AN APPLICATION TO CANADA

    Nov 1, 2005, 00:00

  • PIN6 INFECTIONS CAUSED BY RESISTANT CANDIDA SPECIES- COST-MINIMIZATION ANALISYS OF ANTIFUNGALTHERAPY IN BRAZIL

    Nov 1, 2005, 00:00

  • PSN21 IMPACT OF CORTICOSTEROID-SPARING EFFECT OF AN EMOLLIENT MILK ON FAMILY'S QUALITY OF LIFE OF INFANTS AFFECTED BYATOPIC DERMATITIS

    Nov 1, 2005, 00:00

  • PRS19 IMPACT OF DYSPNOEA ON DAILY ACTIVITIES IN COPD PATIENTS—DEVELOPMENT AND TESTING OF A NEW QUESTIONNAIRE FOR CLINICAL PRACTICE AND CLINICAL TRIALS

    Nov 1, 2005, 00:00

  • PHP24 A SYSTEMATIC REVIEW OF THE EUROPEAN PHARMACEUTICAL MARKET AND THE IMPACT OF EUROPEAN UNION REGULATION AND JURISDICTION

    Nov 1, 2005, 00:00

  • PCV21 COST EFFECTIVENESS ANALYSIS OF BISOPROLOL TREATMENT FOR HEART FAILURE

    Nov 1, 2005, 00:00

  • PO3 CLASSIFYING AND PREDICTING ANTIPSYCHOTIC ADHERENCE AMONG SCHIZOPHRENIA OUTPATIENTS IN EUROPE- A LATENT CLASS ANALYSIS

    Nov 1, 2005, 00:00

  • PMH21 TREATMENT PERSISTENCE- A COMPARISON AMONG PATIENTS WITH SCHIZOPHRENIA WHO WERE INITIATED ON ATYPICAL ANTIPSYCHOTIC AGENTS

    Nov 1, 2005, 00:00

  • PCV79 POSTMYOCARDIAL INFARCTION CARDIAC REHABILITATION IN LOW RISK PATIENTS. RESULTS WITH A COORDINATED PROGRAM OF CARDIOLOGICAL AND PRIMARY CARE

    Nov 1, 2005, 00:00

  • PDB57 TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGYWITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES- THE CANADIAN INSIGHT STUDY

    Nov 1, 2005, 00:00

  • PCN10 THE COST-EFFECTIVENESS OF POST-OPERATIVE RADIOTHERAPY AFTER BREAST CONSERVATION SURGERY IN STAGEI-II BREAST CANCER IN SWEDEN

    Nov 1, 2005, 00:00

  • PCV89 COST-EFFECTIVENESS OF AN EXTENDED FOUR-WEEK FONDAPARINUX PROPHYLAXIS REGIMEN FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY

    Nov 1, 2005, 00:00

  • IC2 PREDICTING THE COST-EFFECTIVENESS OFTHEABT-578 COATED DRIVER CORONARY STENT (ENDEAVOR) IN DE NOVO NATIVE CORONARY ARTERY LESIONS

    Nov 1, 2005, 00:00

  • PSU8 APPLICATION OF (PRO)SPECTIVE STUDY OF PATIENT SATISFACTION (PS) TO MONITOR QUALITY AND TO SUPPORT MANAGEMENT OF HEALTH CARE PROVIDER—AN EXAMPLE OF MEETING ISO 9001-2000 REQUIREMENTS BY THE CARDIOSURGICAL UNIT IN POLAND.

    Nov 1, 2005, 00:00

  • PEY11 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION- COMPARING EARLY AND LATE MACUGEN TREATMENT

    Nov 1, 2005, 00:00

  • PDB28 COST-EFFECTIVENESS ANALYSES OF BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR + HUMAN SOLUBLE INSULIN VERSUS NEUTRAL PROTAMINE HAGEDORM + HUMAN SOLUBLE INSULIN REGIMENS IN GERMANY

    Nov 1, 2005, 00:00

  • PUK25 SPANISH RESEARCH NETWORK ON TRANSPLANTATION- THE SPANISH VERSION OF THE END-STAGE RENAL DISEASE SYMPTOM CHECK-LIST, A USEFUL TOOL FOR EVALUATE THE PERCEIVED HEALTH STATUS OF RENAL TRANSPLANT BEARERS

    Nov 1, 2005, 00:00

  • POB4 COST-OF-ILLNESS ANALYSIS OF JUVENILE OBESITY AND OF CO-MORBIDITYTYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY

    Nov 1, 2005, 00:00

  • PMD1 COST ANALYSIS OF MANAGEMENT STRATEGIES FOR CLOSED AND OPEN GRADE ITIBIAL SHAFT FRACTURES

    Nov 1, 2005, 00:00

  • PO4 ESTIMATING QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS ORTOXICITY USING A MULTIVARIATE FAILURE TIME REGRESSION MODEL

    Nov 1, 2005, 00:00

  • PSN14 CHANGES IN FUNCTIONAL ABILITY AS MEASURED BY DLQI IS CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB

    Nov 1, 2005, 00:00

  • PAS1 COMPARISON OF TREATMENT WITH BUDESONIDE/FORMOTEROL (BUD/FM) PLUS BUD/FM PRN AS SINGLE INHALERTREATMENT VERSUS REGULAR BUD AND FM PLUS FM PRN AS MONOPRODUCTS IN PATIENTS WITH ASTHMA IN GREECE

    Nov 1, 2005, 00:00

  • Abstracts Index

    Nov 1, 2005, 00:00

  • PIN20 STUDYVALIDATION OF QUALITY OF LIFE QUESTIONNAIRE MINI-HIV

    Nov 1, 2005, 00:00

  • HP1 IDENTIFYING PREDICTORS OF OFF-LABEL UTILIZATION PATTERNS OF TWO BIOTECHNOLOGY DRUGS, RECOMBINANT ERYTHROPOIETIN ALFA AND DARBEPOETIN ALFA A MULTI-HOSPITAL STUDY

    Nov 1, 2005, 00:00

  • PEY17 MODELING TREATMENTS FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE RELATED MACULAR DEGENERATION- COST-EFFECTIVENESS METHODS

    Nov 1, 2005, 00:00

  • PEY20 IMPACT OF BEST AND WORST EYE VISUAL ACUITY ON VISION-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND UTILITY IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2005, 00:00

  • PCV61 THE FRENCH CV@GOAL EDUCATIONAL PROGRAM FOR IMPROVING HBP MANAGEMENT BY PATIENTSAND PHYSICIANS- ASSESSMENT OF ITS IMPACT ON PATIENT'S KNOWLEDGE AND PATIENT-PHYSICIAN RELATIONSHIP

    Nov 1, 2005, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2005, 00:00

  • PCV64 HEALTH CARE UTILIZATION OF ANTIHYPERTENSIVE MEDICATION WITHIN THE SLOVAK REPUBLIC

    Nov 1, 2005, 00:00

  • PRS14 HEALTH CARE RESOURCES UTILIZATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACCORDING TO THEIR SEVERITY IN SPAIN

    Nov 1, 2005, 00:00

  • CV1 ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME

    Nov 1, 2005, 00:00

  • PIN8 INCREASED MANAGEMENT NEEDS AND CARE COSTS FOR NURSING HOME RESIDENTS WITH CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA

    Nov 1, 2005, 00:00

  • PDB50 MODELLING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN ABDOMINALLY OBESE PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PSN20 VALIDATION OF THE ITALIAN VERSION OF THE DERMATOLOGY LIFE QUALITY INDEX

    Nov 1, 2005, 00:00

  • PCV57 COST-EFFECTIVENESS OF NEBIVOLOL VERSUS ATENOLOL AND ACE INHIBITOR MONOTHERAPY IN PATIENTS WITH MODERATE HYPERTENSION

    Nov 1, 2005, 00:00

  • PDB5 IMPROVED TREATMENT SATISFACTION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE OR INSULIN GLARGINE

    Nov 1, 2005, 00:00

  • PNL16 THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY

    Nov 1, 2005, 00:00

  • PFM2 FIBROMYALGIA SYNDROME- AN ITALIAN EPIDEMIOLOGICAL SURVEY

    Nov 1, 2005, 00:00

  • PNL4 THE SOCIAL AND ECONOMIC BURDEN OF PAEDIATRIC EPILEPSY IN IRELAND- A PROSPECTIVE STUDY

    Nov 1, 2005, 00:00

  • PEY9 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION- COMPARING MACUGEN TO VISUDYNE

    Nov 1, 2005, 00:00

  • POS1 SYSTEMATIC REVIEW OF IBANDRONATE FOR POSTMENOPAUSAL OSTEOPOROSIS

    Nov 1, 2005, 00:00

  • PSN3 ECONOMIC EVALUATION OF PIMECROLIMUS, A NEW TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS IN HUNGARY

    Nov 1, 2005, 00:00

  • PHP18 GEOGRAPHICAL INFORMATION SYSTEM (GIS) ANALYSIS OF SMALL AREA INEQUALITIES IN DRUG EXPENDITURES IN HUNGARY

    Nov 1, 2005, 00:00

  • PCV85 CLINICAL OUTCOME AND COST-EFFECTIVENESS OF DIFFERENT BYPASS MATERIALS IN VASCULAR SURGERY

    Nov 1, 2005, 00:00

  • Impact of Computer-Generated Personalized Goals on Cholesterol Lowering

    Nov 1, 2005, 00:00

  • PSN7 EPIDEMIOLOGY AND MANAGEMENT OF EXTERNAL GENITAL WARTS (EGW) IN FRANCE

    Nov 1, 2005, 00:00

  • PDB35 THE COST OF DIABETES MELLITUS IN SPAIN

    Nov 1, 2005, 00:00

  • PHP6 DRUG PRICE INDICES 1980-2004 IN FINLAND

    Nov 1, 2005, 00:00

  • PST11 THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH CARE. DOES METHOD USED INFLUENCE OUTCOME?

    Nov 1, 2005, 00:00

  • PNL18 COST-EFFECTIVENESS OF CONTINUOUS DUODENAL DELIVERY OF LEVODOPA (DUODOPA®) IN PATIENTS WITH SEVERE PARKINSON'S DISEASE

    Nov 1, 2005, 00:00

  • PMH15 GALANTAMINE REDUCES CAREGIVER BURDEN- RESULTS FROM A NATURALISTIC STUDY

    Nov 1, 2005, 00:00

  • PIN1 ASSESSING THE EXTERNAL VALIDITY OF DROTRECOGIN ALFA (ACTIVATED) CLINICAL TRIALS IN AN OBSERVATIONAL STUDY USING PROPENSITY SCORE MATCHING TO REDUCE RECRUITMENT BIAS

    Nov 1, 2005, 00:00

  • PEY16 THE PREVALENCE AND COST OF TREATMENT OF PATIENTS TAKING ANTIGLAUCOMA AGENTS FOR GLAUCOMA OR OCULAR HYPERTENSION IN FRANCE

    Nov 1, 2005, 00:00

  • IN2 ASSESSEMENT OF THE ADDITIONAL COST OF DROTRECOGIN ALFA (ACTIVATED) RELATIVE TO STANDARD CARE IN THE TREATMENT OF SEVERE SEPSIS IN A MULTICENTIC OBSERVATIONAL STUDY IN FRANCE

    Nov 1, 2005, 00:00

  • PRS8 COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE NASAL DROPS VERSUS SURGICAL TREATMENT FOR NASAL POLYPOSIS IN POLAND

    Nov 1, 2005, 00:00

  • PCV70 THE COSTS OF METABOLIC SYNDROME

    Nov 1, 2005, 00:00

  • PRS6 ECONOMIC EVALUATION OF TIOTROPIUM AND SALMETEROL IN THE TREATMENT OF COPD IN GREECE

    Nov 1, 2005, 00:00

  • PUK33 DEVELOPMENT AND TESTING OF A COMPOSITE SCALE TO ASSESS THERAPEUTIC RESPONSE IN STRESS URINARY INCONTINENCE

    Nov 1, 2005, 00:00

  • PAL1 DETERMINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE FORTHE ESPRINT-15 QUESTIONNAIRE FOR PATIENTS WITH ALLERGIC RINHITIS

    Nov 1, 2005, 00:00

  • PDB8 CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STATIN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS

    Nov 1, 2005, 00:00

  • PUK4 BUDGET IMPACT ANALYSIS OF MIMPARAAMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL

    Nov 1, 2005, 00:00

  • PST2 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH- AN ECONOMIC EVALUATION FOR THE NETHERLANDS BASED ON THE LIFE-STUDY

    Nov 1, 2005, 00:00

  • PCV41 PORTUGUESE ACTIVE POPULATION HEALTH RELATED QUALITY OF LIFE RESULTS USING THE SF-6D

    Nov 1, 2005, 00:00

  • POS11 AN INTERNATIONAL COMPARISON OF THE IMPACT OF DOSING FREQUENCY ON COMPLIANCE AND PERSISTENCE WITH BISPHOSPHONATE THERAPY, AMONG POST-MENOPAUSAL WOMEN IN THE US, UK AND GERMANY

    Nov 1, 2005, 00:00

  • PMH50 DEVELOPMENT OF A COMPREHENSIVE EMOTIONAL, SOMATIC AND PAINFUL PHYSICAL SYMPTOMS CHECKLIST IN DEPRESSION IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PDB27 COST-EFFECTIVENESS OFACARBOSE IN ADDITION TO EXISTING TREATMENTS IN TYPE-2 DIABETES IN GERMANY

    Nov 1, 2005, 00:00

  • PDB12 BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF ROSIGLITAZONE IN THE TREATMENT OFTYPE-2 DIABETES. THE ITALIAN NHS PERSPECTIVE

    Nov 1, 2005, 00:00

  • PDB25 FIXED COMBINATION METFORMIN PLUS GLIBENCLAMIDE (GLUCOVANCE®) IS COST AND LIFE SAVING COMPARED TO METFORMIN PLUS ROSIGLITAZONE IN TYPE-2 DIABETES PATIENTS IN FRANCE

    Nov 1, 2005, 00:00

  • HP3 PHYSICIAN PRESCRIBING OF SLEEP DISORDER MEDICATIONS IN UNITED STATES OUTPATIENT SETTINGS- FACTORS AFFECTING PRESCRIPTION OF HIGH ABUSE POTENTIAL AND COSTLY MEDICATIONS

    Nov 1, 2005, 00:00

  • PSN2 COST-EFFECTIVENESS ANALYSIS- ALDARA™ (IMIQUIMOD) CREAM, 5% IN THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA IN NORWAY

    Nov 1, 2005, 00:00

  • PCV50 A MULTILEVEL ANALYSIS ON PRESCRIBED STATINES IN A BOLOGNA HEALTH AUTHORITY FROM 2000 TO 2003

    Nov 1, 2005, 00:00

  • PST7 DO PATIENTS WITH ATRIAL FIBRILLATION RECEIVE APPROPRIATE STROKE PREVENTION THERAPY IN PRACTICE?

    Nov 1, 2005, 00:00

  • POS14 ELICITING AND QUANTIFYING PATIENT PREFERENCES FOR DOSING FREQUENCY

    Nov 1, 2005, 00:00

  • PCV87 VITAE THROMBOSIS STUDY- THE PREVALENCE AND BURDEN OF VENOUS THROMBOEMBOLIC DISEASE (VTE) IN EUROPE

    Nov 1, 2005, 00:00

  • PCN36 A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCERAFTERANTHRACYCLINE FAILURE

    Nov 1, 2005, 00:00

  • PSN1 USING THE GENERAL PRACTICE RESEARCH DATABASE TO ESTIMATE THE INCIDENCE, PREVALENCE AND MANAGEMENT OF HYPERHIDROSIS IN THE UK

    Nov 1, 2005, 00:00

  • PDB30 COST-EFFECTIVENESS OF PREVENTIVE INTERVENTIONS IN DIABETES MELLITUS AND ITS (MACROVASCULAR)COMPLICATIONS- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2005, 00:00

  • PDB23 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NPH-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN GERMANY

    Nov 1, 2005, 00:00

  • PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

    Nov 1, 2005, 00:00

  • PCV71 COST-EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH GENERIC SIMVASTATIN IN THE UK NHS

    Nov 1, 2005, 00:00

  • PDB32 ECONOMIC EVALUATION OF THE LAPTOP-STUDY RESULTS

    Nov 1, 2005, 00:00

  • PHP47 EVALUATION OF THE RELATIONSHIP BETWEEN PHARMACEUTICAL PRODUCT PRICE AND HEALTH-RELATED QUALITY OF LIFE USING WHOLESALE ACQUSITION COST AND AVERAGE EFFECT SIZE

    Nov 1, 2005, 00:00

  • PCV38 THIENOPYRIDINE THERAPY IN ACUTE CORONARY SYNDROME PATIENTS RESIDING IN GERMANY

    Nov 1, 2005, 00:00

  • MC3 METAMODELLING FORTHE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS

    Nov 1, 2005, 00:00

  • PHP42 PAYMENT FOR PHARMACY HANDLING COSTS IN THE HOPD- 2006 REIMBURSEMENT IMPLICATIONS

    Nov 1, 2005, 00:00

  • PAS4 THE COST OF ASTHMA EXACERBATIONS OF DIFFERENT SEVERITY LEVELS

    Nov 1, 2005, 00:00

  • PFM5 CROSS-SURVEY OF FRENCH AND PORTUGUESE RHEUMATOLOGISTS GLOBAL MANAGEMENT OF FIBROMYALGIA

    Nov 1, 2005, 00:00

  • PMC21 EVALUATING THE DIFFERENCE BETWEEN AVERAGE WHOLESALE PRICE AND WHOLESALE ACQUISITION COST FOR PHARMACEUTICALS IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • Brief Reflections on Treatment Satisfaction

    Nov 1, 2005, 00:00

  • POS6 IMPACT OF BISPHOSPHONATES ON OSTEOPOROTIC FRACTURES, PATIENT QUALITY OF LIFE AND TREATMENT COSTS-THE CASE OF GERMANY

    Nov 1, 2005, 00:00

  • PSN25 ADULTS WITH ATOPIC DERMATITIS- QUALITY OF LIFE IMPACT

    Nov 1, 2005, 00:00

  • PEY3 INTRA-OCULAR PRESSURE (IOP) CONTROL OF LATANOPROST AND TRAVOPROST MONOTHERAPY IN DAILY PRACTICE

    Nov 1, 2005, 00:00

  • HP7 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN PRIVATE PAYER TRANSPLANT RECIPIENTS

    Nov 1, 2005, 00:00

  • PHP23 A COMPARATIVE ANALYSIS OF THE FINANCING, PRICING AND REIMBURSEMENT SYSTEMS FOR PRESCRIPTION DRUGS IN THE NORDIC COUNTRIES

    Nov 1, 2005, 00:00

  • PGI16 GASTROESOPHAGEAL REFLUX DISEASE (GERD) — PREVALENCE, MANAGEMENT AND COST IN INTERNATIONAL COMPARISON

    Nov 1, 2005, 00:00

  • QL2 TESTING THE CROSS-WALK- SALVAGING CANCER SPECIFIC MEASURES FOR USE IN ECONOMIC EVALUATION

    Nov 1, 2005, 00:00

  • PUK23 VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE (KING'S HEALTH QUESTIONNAIRE) IN BRAZILIAN WOMEN WITH URINARY INCONTINENCE

    Nov 1, 2005, 00:00

  • POS8 CONTENT VALIDATION OF OSTEOPOROSIS TREATMENT PREFERENCE QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • PNL22 THE SYMPTOMATIC, FUNCTIONAL AND QUALITY OF LIFE IMPACT OF MULTIPLE SCLEROSIS. REPORT ON A QUALITATIVE INVESTIGATION OF THE PATIENTS' PERSPECTIVE

    Nov 1, 2005, 00:00

  • PCV76 COST-EFFECTIVENESS ANALYSIS OF THE USE OF ACETYLSALICYLIC ACID COMPARED TO CLOPIDOGREL IN THE SECONDARY PREVENTION OF PATIENTS WITH PREVIOUS MYOCARDIAL INFRACTION

    Nov 1, 2005, 00:00

  • PNL13 IMPLANTABLE SYSTEMS PERFORMANCE REGISTRY (ISPR) A MEDICAL DEVICE AND PATIENT REGISTRY

    Nov 1, 2005, 00:00

  • PCV37 USE OF TIME-STAMPED HOSPITAL DATA TO EXAMINE CARE PATTERNS OF ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2005, 00:00

  • PGI10 COST EFFECTIVENESS OF PROTON PUMP INHIBITOR TRIPLE THERAPY REGIMENS FOR HELICOBACTER PYLORI ERADICATION IN THE PRIMARY CARE SETTING IN IRELAND

    Nov 1, 2005, 00:00

  • PCN25 INFLUENCE OF THE PORTION OF MEDICAL EXPENSE PAID INDIVIDUALLY ON PHYSICIANS'ATTITUDE TOWARDS CANCER TREATEMENT IN JAPAN

    Nov 1, 2005, 00:00

  • PSU2 COST-EFFECTIVENESS OF TWO REGIMENS OF TOTAL INTRAVENOUS ANESTHESIA USING INFUSION PUMP IN MEXICO

    Nov 1, 2005, 00:00

  • PMC2 REVIEW OF THE ACTIVITIES OF THE ISOQOL TRANSLATION AND CULTURAL ADAPTATION (TCA) SPECIAL INTEREST GROUP (SIG)

    Nov 1, 2005, 00:00

  • QL5 CLINICAL RESPONSES TO TREATMENT AND CHANGES IN THE DERMATOLOGY LIFE QUALITY INDEX (DLQI) IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB

    Nov 1, 2005, 00:00

  • POS12 HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND AN INADEQUATE RESPONSE TO ANTI-OSTEOPOROSIS MEDICATION- BASELINE RESULTS OF THE FRENCH COHORT FROM THE OBSERVATIONAL STUDY OF SEVERE OSTEOPOROSIS (OSSO)

    Nov 1, 2005, 00:00

  • PGI22 BURDEN OF ILLNESS IS HIGHEST IN PATIENTS WITH SEVERE PAIN SYMPTOMS

    Nov 1, 2005, 00:00

  • PCV56 EVALUATION OF COSTS RELATED TO HYPERTENSION IN PATIENTS WITH CONCOMITANT DISEASES IN POLAND

    Nov 1, 2005, 00:00

  • PAR20 EFFECTS OF LONG-TERM ADALIMUMAB THERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONGSTANDING, SEVERE RHEUMATOID ARTHRITIS (RA)—RESULTS FROM A 3-YEAR FOLLOW-UP STUDY

    Nov 1, 2005, 00:00

  • PCV27 COSTS AND OUTCOMES AFTER FIRST HEART FAILURE HOSPITAL ADMISSION- A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES

    Nov 1, 2005, 00:00

  • PUK13 COST-MINIMISATION-ANALYSIS ON THE TREATMENT OF URINARY INCONTINENCE WITH TROSPIUM CHLORIDE IN COMPARISON WITH OXYBUTYNIN IN GERMANY

    Nov 1, 2005, 00:00

  • PEY4 EVALUATION OF INCREMENTAL EFFICACY OF LATANOPROST-TIMOLOL IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA USING RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY GLAUCOMA DATABASE

    Nov 1, 2005, 00:00

  • MC2 IMPACT OF THE PROPENSITY SCORE ESTIMATION METHOD WHEN MATCHING PATIENTS TO REDUCE RECRUITMENT BIAS IN OBSERVATIONAL STUDIES

    Nov 1, 2005, 00:00

  • POS13 UNDERSTANDING AND ASSESSING TIBIA FRACTURE ON QUALITY OF LIFE; CONCEPTUAL MODELAND NEW DISEASE SPECIFIC HR-QOL MEASURE

    Nov 1, 2005, 00:00

  • PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER- COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN ...

    Nov 1, 2005, 00:00

  • PCV3 A PHARMACO-ECONOMIC EVALUATION OF AGGRESSIVE CHOLESTEROL LOWERING AFTER ACUTE CORONARY SYNDROME IN BELGIUM- A SHORT-TERM AND LONG-TERM ASSESSMENT

    Nov 1, 2005, 00:00

  • PGI5 THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2B (I2KD) PLUS RIBAVIRIN VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC) IN A DEVELOPING COUNTRY—BRAZIL

    Nov 1, 2005, 00:00

  • PMH43 CLINICAL COMPARISON OF SSRIS AND SNRIS IN MAJOR DEPRESSIVE DISORDER- A META-ANALYSIS

    Nov 1, 2005, 00:00

  • PAR5 OSTEOARTHRITIS-CHONDROITIN SULFATE LONG TERM UTILIZATION REDUCES CONSUMPTION OF COXIBS, NSAIDS ANALGESICS

    Nov 1, 2005, 00:00

  • PEY8 EYE ADVERSE EFFECTS ASSOCIATED WITH POLYVINYL ALCOHOL TEAR DROPS AFTER LASER ASSISTED SUBEPITHELIAL KERATECTOMY (LASEK)

    Nov 1, 2005, 00:00

  • PST4 COST-CONSEQUENCE ANALYSIS FOR THE HANDMASTER IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • POS7 EVALUATION OF DISTRIBUTION OF HIP REPLACEMENT IN HUNGARY ACCORDING TO GEOGRAPHICAL REGIONS AND AGE GROUPS

    Nov 1, 2005, 00:00

  • PCV88 TREATMENT PATTERN, RESOURCE UTILIZATION AND COSTS OF INPATIENTTHROMBOPROPHYLAXIS IN POLAND

    Nov 1, 2005, 00:00

  • PRS2 PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION

    Nov 1, 2005, 00:00

  • HP5 TREATMENT PATTERNS AMONG POSTMENOPAUSAL OSTEOPOROTIC WOMEN STARTING ON DAILY OR WEEKLY BISPHOSPHONATE THERAPY

    Nov 1, 2005, 00:00

  • PHP12 PRICING POLICIES FOR THE PHARMACEUTICAL MARKET—AN INTERNATIONAL PERSPECTIVE

    Nov 1, 2005, 00:00

  • PHP35 AGE AND GENDER IN PHARMACEUTICAL EXPENDITURE- ATOOL FOR RISK CALCULATION

    Nov 1, 2005, 00:00

  • PMH1 COST EFFECTIVENESS OF ESCITALOPRAM IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)

    Nov 1, 2005, 00:00

  • PCV91 COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH FONDAPARINUX TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING UK AND DUTCH ESTIMATES OF COSTS

    Nov 1, 2005, 00:00

  • PCN38 ASSESSING THE IMPACT ON STAFF RESOURCE AND PATIENT WAITING TIME OF A SWITCH FROM IV TO ORAL CHEMOTHERAPY- TIME AND MOTION MODEL FOR HTAS

    Nov 1, 2005, 00:00

  • PSN22 SENSITIVE SKIN- IMPACT ON QUALITY OF LIFE

    Nov 1, 2005, 00:00

  • PCN37 IMPACT OF HEALTH CARE REFORMSAND CHANGING PAYMENT MECHANISMS ON HEALTH ECONOMIC EVALUATIONS IN GERMANY

    Nov 1, 2005, 00:00

  • PMH3 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GROWN-UPS- ADMINISTRATIVE DATA ON CO-EXISTING CONDITIONS

    Nov 1, 2005, 00:00

  • CV2 COSTS OF CARDIOVASCULAR DISEASE- A CASE-CONTROL STUDY

    Nov 1, 2005, 00:00

  • PAR19 CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)

    Nov 1, 2005, 00:00

  • PCN48 QUALITY OF LIFE AND RESOURCE UTILIZATION OF PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER- A CANADIAN PERSPECTIVE

    Nov 1, 2005, 00:00

  • PEY10 COMBIGAN—COST-MINIMIZATION ANALYSIS OF BRIMONIDINE/TIMOLOL FIXED COMBINATION IN THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA

    Nov 1, 2005, 00:00

  • UB2 QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN CROHN'S DISEASE

    Nov 1, 2005, 00:00

  • PMH5 A MODELLED ECONOMIC EVALUATION OF ATOMOXETINE (STRATTERA) FOR THE TREATMENT OF THREE PATIENT GROUPS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

    Nov 1, 2005, 00:00

  • PCV72 UTILIZATION PATTERNS OF ASPIRIN AMONG NSAID TREATED SUBJECTS WITH VARYING CARDIOVASCULAR RISK PROFILES IN A HEALTH BENEFITS POPULATION

    Nov 1, 2005, 00:00

  • PMH40 LONG-TERM MAINTENANCE OF INITIAL HEALTH RELATED QUALITY OF LIFE (HRQL) IMPROVEMENTS GAINED THROUGH ANTIPSYCHOTIC TREATMENT- 24-MONTH RESULTS FROM THE SCHIZOPHRENIA HEALTH OUTCOMES (SOHO) STUDY

    Nov 1, 2005, 00:00

  • HP4 PRIMARY CARE AND GATEKEEPER MODELS IN GERMANY — WHAT DO THE PATIENTS WANT?

    Nov 1, 2005, 00:00

  • PST12 THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH CARE.WHICH METHOD IS MOST SUITABLE FOR HEALTHY AND COGNITIVELY IMPAIRED POPULATION?

    Nov 1, 2005, 00:00

  • POS3 RISK FOR OSTEOPOROTIC FRACTURES IS REDUCED IN PERSISTENT BISPHOSPHONATE USERS

    Nov 1, 2005, 00:00

  • PCV51 PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN 10/20MG) IN SPAIN

    Nov 1, 2005, 00:00

  • Association between the Erectile Dysfunction Inventory of Treatment Satisfaction and the Self-Esteem and Relationship Questionnaire Following Treatment with Sildenafil Citrate for Men with Erectile Dysfunction

    Nov 1, 2005, 00:00

  • PCV2 COST-EFFECTIVENESS OF AN INTENSIVE TREATMENT WITH 80MGATORVASTATINVS 40 MG PRAVASTATIN IN ACUTE CORONARY SYNDROME- AN ECONOMIC EVALUATION BASED ON THE PROVE-IT (PRAVASTATIN ORATORVASTATIN EVALUATION AND INFECTION THERAPY)

    Nov 1, 2005, 00:00

  • PPN6 A UK PHARMACOECONOMIC MODEL OF PARENTERAL PARECOXIB VERSUS OPIOID ANALGESIA FOLLOWING MAJOR SURGERY

    Nov 1, 2005, 00:00

  • PIN13 SYSTEMATIC REVIEW ON THE SHARE OF ANTIBIOTIC THERAPY COST IN RELATION OVERALL DIRECTTREAMENT COSTS OF MOST FREQUENT NOSOCOMIAL AND COMMUNITY ACQUIRED INFECTIONS IN ADULTS

    Nov 1, 2005, 00:00

  • PSU5 FACTORS ASSOCIATED WITH BLOOD TRANSFUSION COSTS DURING AND FOLLOWING SPINAL SURGERY IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PDB7 THE METABOLIC EFFECTS OF ORLISTAT AND ROSIGLITAZONE ON INSULIN ACTION IN A GROUP OF CHINESE PATIENTS AFFECTED BYTHE METABOLIC SYNDROME

    Nov 1, 2005, 00:00

  • PCV10 DRIVERS OF UNDERUSE OF VITAMIN K ANTAGONISTS IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION IN FRANCE- THE ENSEFAL STUDY

    Nov 1, 2005, 00:00

  • PCV83 COST-EFFECTIVENESS OF ENDOVASCULARVERSUS CONVENTIONAL ABDOMINAL AORTIC ANEURYSM REPAIR AT ONE YEAR; RESULTS OF A RANDOMIZED TRIAL

    Nov 1, 2005, 00:00

  • UH3 OVERACTIVE BLADDER IN MALES- A GROWING HEALTH AND ECONOMIC BURDEN

    Nov 1, 2005, 00:00

  • PHM6 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH HAEMOPHILIA A SWITCHED TO PROPHYLACTIC REPLACEMENT TREATMENT

    Nov 1, 2005, 00:00

  • PAR7 HEALTH CARE UTILIZATION AND EXPENDITURE OF TWO PROGRAMS FOR OSTEOARTHRITIS OF THE KNEE AND HIP- ASSESSMENT AND IMPACT IN REAL-LIFE CONDITIONS

    Nov 1, 2005, 00:00

  • PCV7 COSTS OF DIAGNOSIS OF ARRHYTHMOGENIC RIGTH VENTRICULAR CARDIOMYOPATHY IN INDIVIDUALS WITH A FAMILY HISTORY OF THE DISEASE IN POLAND

    Nov 1, 2005, 00:00

  • PUK5 ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS IN HUNGARY

    Nov 1, 2005, 00:00

  • PCV90 COST EFFECTIVENESS OF FONDAPARINUX COMPARED WITH ENOXAPARIN FOR EXTENDED PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING DUTCH ESTIMATES OF COSTS

    Nov 1, 2005, 00:00

  • PNL1 EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV MODEL ESTIMATING THE COST EFFECTIVENESS OF MEMANTINE VERSUS STANDARD CARE IN ALZHEIMER DISEASE FROM A UK PERSPECTIVE

    Nov 1, 2005, 00:00

  • PIH5 SENIORS' PHARMACEUTICAL EXPENDITURES IN THE CZECH REPUBLIC

    Nov 1, 2005, 00:00

  • PHM7 DISEASE STATE AND QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES- A REVIEW OF INSTRUMENTS, DISEASE BURDEN, AND PREDICTIVE FACTORS FOR OUTCOMES

    Nov 1, 2005, 00:00

  • PMH36 CASE STUDY OF PATTERN MIXTURE APPROACH FOR COMBINING COMPLETION RATESAND EFFICACY FOR CLINCALLY MEANINGFULL OUTCOMES IN SCHIZOPHRENIA DRUG TRIALS

    Nov 1, 2005, 00:00

  • In Memoriam- Alan Williams (1928–2005)

    Nov 1, 2005, 00:00

  • PHP40 THE IMPACT ON DECISION-MAKING OF CHANGING COST-EFFECTIVENESS OF HEALTH TECHNOLOGIES OVERTIME

    Nov 1, 2005, 00:00

  • HP2 PHARMACIST RESPONSE TO COMPUTER-GENERATED DRUG THERAPY ALERTS IN A LONG TERM CARE SETTING

    Nov 1, 2005, 00:00

  • PDB9 PROJECTED IMPACT ON CORONARY HEART DISEASE AT 5, 10 AND 35 YEARS OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PCV24 COST-EFFECTIVENESS ANALYSIS OF ALDOSTERONE BLOCKADE WITH EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION (EPHESUS) IN THE FRENCH CONTEXT

    Nov 1, 2005, 00:00

  • PHP3 ECONOMIC IMPACT OF A DEVICE FOR PREPARING STERILE SOLUTIONS IN THE MT. SINAI HOSPITAL PHARMACY

    Nov 1, 2005, 00:00

  • PUK29 DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE SYMPTOM CHECKLIST IN URINARY INCONTINENCE

    Nov 1, 2005, 00:00

  • PCN41 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ADVANCED COLORECTAL CANCER (ACC)- “CCRA-QOL”

    Nov 1, 2005, 00:00

  • PIN2 ECONOMIC IMPLICATION OF HEPATITIS B VIRAL (HBV) LOAD REDUCTION FOR ENTEVAVIR IN HEPATITIS B E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS

    Nov 1, 2005, 00:00

  • PUK18 ESTIMATION AND ANALYSIS OF DIRECT MEDICAL COST OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN DIALYSIS PATIENTS

    Nov 1, 2005, 00:00

  • HP6 EFFECT OF CO-PAYMENT ON COMPLIANCE TO STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION

    Nov 1, 2005, 00:00

  • PAS6 CLINICAL OUTCOME OF CHRONIC ASTHMA

    Nov 1, 2005, 00:00

  • PIN29 ESTIMATED ANNUAL NHS COSTS OF HUMAN PAPILLOMAVIRUS (HPV) RELATED DISEASES IN THE UK

    Nov 1, 2005, 00:00

  • PDB61 PERCEIVED HEALTH CARE INFORMATION ON DIABETES- MEASUREMENT OF PATIENT SATISFACTION

    Nov 1, 2005, 00:00

  • PMC5 A STANDARD SET OF UNIT COSTS FOR GERMANY

    Nov 1, 2005, 00:00

  • PST5 COST AND OUTCOMES AFTER FIRST STOKE HOSPITAL ADMISSION- A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES

    Nov 1, 2005, 00:00

  • PHP4 ECONOMIC COMPARISON OF TWO XENETIX® 300 PRESENTATIONS

    Nov 1, 2005, 00:00

  • PPN3 BURDEN OF ILLNESS OF PATIENTS WITH NEUROPATHIC PAIN IN PRIMARY CARE IN THE UK

    Nov 1, 2005, 00:00

  • PIN23 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE UK

    Nov 1, 2005, 00:00

  • PDB1 DIABETIC PERIPHERAL NEUROPATHY- EVALUATION OF THE INTER-ASSOCIATION BETWEEN THE RANGES OF NEUROPATHIC SYMPTOMS

    Nov 1, 2005, 00:00

  • PCV16 KNOWLEDGE AND USE OF TREATMENT GUIDELINES FOR STROKE PREVENTION OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION (AFIB) IN GERMANY

    Nov 1, 2005, 00:00

  • PUK27 PSYCHOMETRIC VALIDATION OF THE UK ENGLISH INCONTINENCE-SPECIFIC QUALITY OF LIFE MEAURE (I-QOL)

    Nov 1, 2005, 00:00

  • UH1 COST AND QUALITY OF LIFE OF HEMOPHILIA- COMPARISON BETWEEN PATIENTS WITH AND PATIENTS WITHOUT INHIBITORS

    Nov 1, 2005, 00:00

  • PCV9 THE EFFECT OF ANTICOAGULATION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION-COMPARING EFFICACY AND EFFECTIVENESS

    Nov 1, 2005, 00:00

  • IN1 COSTS ASSOCIATED WITH SHORTER DURATION OF ANTIBIOTIC THERAPY IN HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA

    Nov 1, 2005, 00:00

  • PSU7 “TECHNO-MARKERS” FOR THE ASSESSMENT OF HEALTH TECHNOLOGY UTILIZATION

    Nov 1, 2005, 00:00

  • PEY19 METHODS FOR A POPULATION-BASED INTERNATIONAL STUDY ON THE BURDEN OF ILLNESS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2005, 00:00

  • PSN6 COST-EFFECTIVENESS OF BRIVUDINE COMPARED TO ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN GERMANY

    Nov 1, 2005, 00:00

  • PO2 DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE TO EVALUATE SEVERITY OF SYMPTOMS IN PATIENTS WITH IBS-C AND IBS-A

    Nov 1, 2005, 00:00

  • PHM9 HOW PATIENTS WITH HAEMOPHILIA ARE SATISFIED WITH THEIR TREATMENT

    Nov 1, 2005, 00:00

  • PMH10 A MODELLED ECONOMIC EVALUATION COMPARING ATOMOXETINEWITH CURRENT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PAR15 TARGETED ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA- EARLY ANALYSIS FROM A QUALITATIVE STUDY

    Nov 1, 2005, 00:00

  • PUK8 COST-EFFECTIVENESS OF SCREENING FOR ALBUMINURIA AND SUBSEQUENT TREATMENT WITH AN ACE-INHIBITOR; A PHARMACO-ECONOMIC ANALYSIS

    Nov 1, 2005, 00:00

  • PCN5 THE COST OF SECOND-LINE TREATMENT OF OVARIAN CANCER IN POLISH SETTINGS

    Nov 1, 2005, 00:00

  • PSU6 DIFFERENCES IN BLOOD TRANSFUSION COSTS BY HIP AND KNEE REPLACEMENT AND REVISION SURGERY SUBTYPES

    Nov 1, 2005, 00:00

  • PMH37 THE ECONOMIC BURDEN OF SCHIZOPHRENIA IN THE UNITED STATES IN 2002

    Nov 1, 2005, 00:00

  • PRS4 INHALED CORTICOSTEROIDS AND BROCHODILATORS FOR SEVERE AND VERY SEVERE COPD PATIENTS- COST-EFFECTIVENESS AND HEALTH CARE BUDGET IMPACT IN ITALY

    Nov 1, 2005, 00:00

  • PRS9 COST OF COMMUNITY ACQUIRED PNEUMONIA (CAP) TREATMENT WITH KETEK (TELITHROMYCIN) VS CLARITHROMYCIN FROM PUBLIC PAYER PERSPECTIVE IN POLAND

    Nov 1, 2005, 00:00

  • PPN1 COGNITIVE FUNCTION IMPAIRMENT IN PATIENTS WITH NEUROPATHIC PAIN

    Nov 1, 2005, 00:00

  • PCN46 WHAT ARE THE PSYCHOSOCIAL CONSEQUENCES OF AN ABNORMAL SCREENING-MAMMOGRAPHY?

    Nov 1, 2005, 00:00

  • PSN23 FACTORS INFLUENCING QUALITY OF LIFE IN ATOPIC DERMATITIS

    Nov 1, 2005, 00:00

  • PEY5 COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP)- RESULTS OF A META-ANALYSIS

    Nov 1, 2005, 00:00

  • An Economic Evaluation of Triptan Products for Migraine

    Nov 1, 2005, 00:00

  • PCV1 COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN HUNGARY

    Nov 1, 2005, 00:00

  • MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS

    Nov 1, 2005, 00:00

  • PMC26 DEVELOPMENT AND VALIDATION OF A DUTCH VERSION OF THE LONDON HANDICAP SCALE

    Nov 1, 2005, 00:00

  • POB7 COSTS AND HEALTH CARE CONSUMPTIONS IN THE ABDOMINALLY OBESE POPULATION

    Nov 1, 2005, 00:00

  • PMC22 RELATIVE WEIGHTS ASSIGNED TO PHARMACY PROCEDURES- OPPS METHODS DESIGN AND CONCEPTS

    Nov 1, 2005, 00:00

  • PNL17 A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE) WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND

    Nov 1, 2005, 00:00

  • PNL21 THE COST OF MULTIPLE SCLEROSIS (MS) IN EUROPE

    Nov 1, 2005, 00:00

  • PCV39 THE EFFECT OF GENDER ON HEALTH-RELATED QUALITY OF LIFE AFTER CORONARY STENT IMPLANTATION

    Nov 1, 2005, 00:00

  • PSN11 PREDICTORS OF HEALTH CARE OUTCOMES AND COSTS RELATED TO MEDICATION USE IN PATIENTS WITH ACNE IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PMH26 USING CLAIMS DATA TO ESTIMATE THE ANNUAL PREVALENCE OF SCHIZOPHRENIA IN THE UNITED STATES, 2002

    Nov 1, 2005, 00:00

  • POB6 MODIFICATION OF LIFE STYLE AND OBESITY MANAGEMENT IN PRIMARY CARE

    Nov 1, 2005, 00:00

  • PMH24 GEO OBSERVATIONAL STUDY- 24 MONTHS CHARACTERISTICS OF SOCIOECONOMIC AND CLINICAL STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

    Nov 1, 2005, 00:00

  • PGI14 WORK ABSENTEEISM IN IRRITABLE BOWEL SYNDROME (IBS)- MEASURING DAYSVS HOURS MISSED

    Nov 1, 2005, 00:00

  • Economic Burden of Patients with Anemia in Selected Diseases

    Nov 1, 2005, 00:00

  • PMH25 EFFECTIVENESS AND TOLERABILITY OUTCOMES OF RISPERIDONE LONG-ACTING INJECTION COMPARED TO CONVENTIONAL DEPOT ANTIPSYCHOTICS IN A LARGE CANADIAN PSYCHIATRIC HOSPITAL

    Nov 1, 2005, 00:00

  • PHM8 THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON OVERLOAD (IO)

    Nov 1, 2005, 00:00

  • PST3 CLOPIDOGREL VERSUS ASPIRIN IN HIGH-RISK PATIENTS WITH RECENT ISCHEMIC STROKE ORTRANSIENT ISCHEMIC ATTACK- COST-EFFECTIVENESS ANALYSIS IN ITALY

    Nov 1, 2005, 00:00

  • PCV74 A BUDGET IMPACT MODEL FOR EPLERENONE IN THE TREATMENT OF HEART FAILURE POST MYOCARDIAL INFARCTION

    Nov 1, 2005, 00:00

  • PMC24 USE OF PHARMACOECONOMICS/HEALTH ECONOMIC TOOL (PE/HE) IN LOCAL HEALTH CARE DECISION MAKING (DM)

    Nov 1, 2005, 00:00

  • PCV82 COST-UTILITY OF CILOSTAZOL FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN SCOTLAND

    Nov 1, 2005, 00:00

  • PAR2 METAL ON METAL (MOM) HIP RESURFACING (BIRMINGHAM HIP RESURFACING (BHR)) IN YOUNG PATIENTS WITH SEVERE HIP DAMAGE—A COST UTILITY ANALYSIS

    Nov 1, 2005, 00:00

  • PCN4 COST OF CARE AND ECONOMIC IMPACT OF CETUXIMAB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

    Nov 1, 2005, 00:00

  • PRS10 PROJECTING THE FUTURE COSTS OF ASTHMA AND COPD IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PUK32 VALIDATION OF THE INTERNATIONAL PROSTATE SYMPTOMS SCORE IN ITALIAN WOMEN WITH LUTS.THE FLOW STUDY

    Nov 1, 2005, 00:00

  • PMH9 STIMULANT MEDICATION TREATMENT OF ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER IS ASSOCIATED WITH DECREASED EMERGENCY DEPARTMENT COSTS AND UTILIZATION- POPULATION-BASED STUDY

    Nov 1, 2005, 00:00

  • PR1 EVALUATION OF PREFERENCES IN GENITAL HERPES TREATMENT USING A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2005, 00:00

  • PDB42 IMPROVING DIABETES CARE MANAGEMENT ACROSS A SET OF COMPREHENSIVE MEASURES IN A MEDICAID MANAGED CARE ORGANIZATION

    Nov 1, 2005, 00:00

  • PCN11 ECONOMIC EVALUATION OF BORTEZOMIB IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS IN CANADA

    Nov 1, 2005, 00:00

  • PHP45 APPRAISAL OF FIVE NEW OUT-OF-HOURS (OOH) PRIMARY CARE CENTRES IN THE PARISIAN REGION- “MAISONS MÉDICALES DE GARDE (MMG)”

    Nov 1, 2005, 00:00

  • PIN10 ANTIMICROBIAL TREATMENT OF ACUTE OTITIS MEDIA AND ITS PHARMACOECONOMIC ANALYSIS IN SLOVAKIA

    Nov 1, 2005, 00:00

  • PMC28 ITEM RESPONSE BIAS IN INSTRUMENTAL ACTIVITY DAILY LIVING SCALE IN ASIAN OLDER ADULTS

    Nov 1, 2005, 00:00

  • PGI12 THE COSTS OF ACUTE-ON-CHRONIC LIVER FAILURE—A BOTTOM-UP ANALYSIS BASED ON INDIVIDUAL PATIENT DATA

    Nov 1, 2005, 00:00

  • PMC27 THE DEVELOPMENT OF A TREATMENT SATISFACTION QUESTIONNAIRE FOR IRON OVERLOAD (IO) PATIENTS ON CHELATION THERAPY (CT)

    Nov 1, 2005, 00:00

  • PMH42 COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE- A NATURALISTIC STUDY

    Nov 1, 2005, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167 (current)
  • 168
  • 169
  • 170
  • »